NEW YORK (GenomeWeb News) – Hologic said today that its proposed $580 million acquisition of Third Wave Technologies has received from the Federal Trade Commission early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
 
Hologic announced two weeks ago that it will acquire Third Wave Technologies for $11.25 per share, a 24 percent premium to Third Wave’s average trading price during the preceding three months. 
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.